Bristol-Myers Squibb Co (BMY) : Winslow Capital Management reduced its stake in Bristol-Myers Squibb Co by 9.8% during the most recent quarter end. The investment management company now holds a total of 6,949,377 shares of Bristol-Myers Squibb Co which is valued at $421,340,728 after selling 755,259 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Bristol-Myers Squibb Co makes up approximately 1.62% of Winslow Capital Management’s portfolio.
Other Hedge Funds, Including , Van Hulzen Asset Management boosted its stake in BMY in the latest quarter, The investment management firm added 2,501 additional shares and now holds a total of 29,732 shares of Bristol-Myers Squibb Co which is valued at $1,802,651. Bristol-Myers Squibb Co makes up approx 1.00% of Van Hulzen Asset Management’s portfolio.Maryland Capital Management reduced its stake in BMY by selling 6,006 shares or 23.55% in the most recent quarter. The Hedge Fund company now holds 19,495 shares of BMY which is valued at $1,181,982. Bristol-Myers Squibb Co makes up approx 0.18% of Maryland Capital Management’s portfolio.Aull Monroe Investment Management Corp reduced its stake in BMY by selling 500 shares or 2.38% in the most recent quarter. The Hedge Fund company now holds 20,525 shares of BMY which is valued at $1,237,658. Bristol-Myers Squibb Co makes up approx 0.70% of Aull Monroe Investment Management Corp’s portfolio.Wedbush Securities Inc boosted its stake in BMY in the latest quarter, The investment management firm added 13,153 additional shares and now holds a total of 51,717 shares of Bristol-Myers Squibb Co which is valued at $3,868,432. Bristol-Myers Squibb Co makes up approx 0.63% of Wedbush Securities Inc’s portfolio.
Bristol-Myers Squibb Co opened for trading at $59.51 and hit $60.04 on the upside on Tuesday, eventually ending the session at $59.86, with a gain of 1.01% or 0.6 points. The heightened volatility saw the trading volume jump to 1,05,82,599 shares. Company has a market cap of $100,018 M.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Investors should note that on Aug 3, 2016, Bristol-Myers Squibb Co announced a cash dividend of $0.3800. The company’s management has announced Oct 5, 2016 as the ex-dividend date and fixed the record date on Oct 7, 2016. The payable date has been fixed on Nov 1, 2016.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.Shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold” and Lowered the Price Target to $ 62 from a previous price target of $68 .
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.